Gold bars to be exempt from tariffs, White House clarifies
LOUISVILLE - BrightSpring Health Services (NASDAQ: BTSG), a $3.75 billion market cap healthcare provider with impressive revenue of $11.86 billion in the last twelve months, announced Wednesday that its specialty pharmacy, Onco360, has been selected as the national pharmacy partner for several newly approved therapies targeting advanced cancers and rare genetic disorders. According to InvestingPro data, the company has demonstrated remarkable performance with a 103% return over the past year.
According to the company’s press release, Onco360 will provide access, education, data, and support for treatments addressing advanced ovarian and lung cancers, as well as neurofibromatosis type 1. As a prominent player in the Healthcare Providers & Services industry, BrightSpring’s expansion aligns with analysts’ expectations of growing net income this year, as reported by InvestingPro.
The specialty pharmacy has been named a pharmacy partner for three specific medication therapies: GOMEKLI for neurofibromatosis type 1 patients with symptomatic plexiform neurofibromas; AVMAPKI FAKZYNJA CO-PACK for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy; and IBTROZI for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
"At Onco360, we continue to partner with innovators and manufacturers to deliver groundbreaking medicines and therapies to patients facing serious, life-threatening conditions," said BrightSpring President and CEO Jon Rousseau in the statement.
Onco360, founded in 2003, operates as an independent oncology pharmacy with a network of specialty pharmacies accredited by URAC and ACHC. The company serves oncologists, patients, hospitals, cancer centers, manufacturers, health plans, and payers.
BrightSpring Health Services provides home and community-based pharmacy and health solutions across all 50 states, serving over 400,000 customers, clients, and patients daily through various service lines including pharmacy, home health care, primary care, and rehabilitation and behavioral health. The company maintains a strong financial position with a GREAT Financial Health Score of 3.1 according to InvestingPro, which offers comprehensive analysis and 10 additional ProTips about BTSG’s investment potential in its detailed Pro Research Report.
In other recent news, BrightSpring Health Services reported a strong start to 2025 with a 26% year-over-year increase in revenue, reaching $2.9 billion for the first quarter. Despite the revenue growth, the company’s earnings per share (EPS) of $0.19 fell slightly short of the forecasted $0.20. Mizuho Securities responded by raising its price target for BrightSpring Health to $26.00, maintaining an Outperform rating due to the company’s robust performance and strategic market positioning. UBS also reiterated its Buy rating with a $31.00 price target, highlighting consistent growth trends. Additionally, BrightSpring announced a secondary offering where existing stockholders, including affiliates of KKR, plan to sell 14 million shares. The company will not receive any proceeds from this transaction. At its recent annual meeting, stockholders elected two Class I directors and ratified KPMG LLP as the independent accounting firm for the fiscal year. BrightSpring also disclosed strategic leadership additions and new sales hires to bolster its home health and hospice division.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.